EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study

Masatoshi Kudo, Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, Shigeo Shimose, Kazushi Numata, Yuzo Kodama, Shinji Itoh, Yasuhito Tanaka, Hidekatsu Kuroda, Hiroshi Aikata, Atsushi Hiraoka und 5 weitere

Liver Cancer · 19.06.2025 · 15 (1) · 104-116

DOI: 10.1159/000546899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 19.06.2025. Verfasst von Masatoshi Kudo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Intermediate-stage hepatocellular carcinoma (HCC) presents varying tumor burdens. For patients unsuitable for transcatheter arterial chemoembolization (TACE) due to high tumor burden, recent guidelines recommend systemic therapy. This study evaluates the efficacy and safety of atezolizumab plus bevacizumab for TACE-unsuitable patients with unresectable intermediate-stage HCC beyond up-to-seven criteria.

Methods

This prospective, phase II, single-arm, non-blinded study enrolled TACE-naïve patients with unresectable intermediate-stage HCC beyond up-to-seven criteria, Child-Pugh A, no previous systemic therapy, and ECOG Performance Status score of 0–1 from 35 sites in Japan. Patients received atezolizumab 1,200 mg and bevacizumab 15 mg/kg every 3 weeks. The primary endpoint was the 6-month progression-free survival (PFS) rate by modified RECIST (mRECIST). Key secondary endpoints included the objective response rate (ORR) and safety. Exploratory endpoints examined individual changes in tumor size, comparison by inverse probability weighting (IPW) of data with retrospective historical data of TACE-treated patients, and conversion rate to a curative intent therapy.

Results

In total, 74 patients were enrolled from December 2020 to September 2021 (median follow-up, 15.1 months). The 6-month PFS rate by mRECIST was 66.8% (90% CI: 56.8, 75.0), and the lower limit of the 90% CI exceeded the pre-specified threshold of 55%. ORR by mRECIST was 40.5%. After treatment with atezolizumab plus bevacizumab, 10 patients, including 5 patients who had a tumor burden beyond the up-to-11 criteria at baseline, were able to transition to curative intent therapy. PFS by mRECIST by IPW was 9.2 months with atezolizumab plus bevacizumab versus 5.7 months with TACE (hazard ratio 0.67, p = 0.029). Adverse events (AEs), mostly hypertension, proteinuria, and malaise, were common. AEs requiring corticosteroids occurred in 10 patients (13.5%).

Conclusion

Atezolizumab plus bevacizumab appears beneficial as first-line treatment for TACE-unsuitable patients with unresectable intermediate-stage unresectable HCC beyond up-to-seven criteria. Future strategies utilizing multimodal approaches may further improve outcomes.

Schlagwörter

Stichwörter der Autor:innen

AtezolizumabBevacizumabHepatocellular carcinomaPhase II trial

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
  • Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Zitieren

APA

Kudo, M., Ueshima, K., Tsuchiya, K., Yamashita, T., Shimose, S., Numata, K., Kodama, Y., Itoh, S., Tanaka, Y., Kuroda, H., Aikata, H., Hiraoka, A., Moriguchi, M., Tateishi, R., Ogasawara, S., Yamamoto, K., & Ikeda, M. (2025). Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study. Liver Cancer, 15(1), 104-116. https://doi.org/10.1159/000546899

Vancouver

Kudo M, Ueshima K, Tsuchiya K, Yamashita T, Shimose S, Numata K, et al. Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study. Liver Cancer. 2025;15(1):104-116. doi:10.1159/000546899

BibTeX
@article{Kudo2025,
  author = {Kudo, Masatoshi and Ueshima, Kazuomi and Tsuchiya, Kaoru and Yamashita, Tatsuya and Shimose, Shigeo and Numata, Kazushi and Kodama, Yuzo and Itoh, Shinji and Tanaka, Yasuhito and Kuroda, Hidekatsu and Aikata, Hiroshi and Hiraoka, Atsushi and Moriguchi, Michihisa and Tateishi, Ryosuke and Ogasawara, Sadahisa and Yamamoto, Kouji and Ikeda, Masafumi},
  title = {Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study},
  journal = {Liver Cancer},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {104--116},
  doi = {10.1159/000546899}
}
Kostenlos starten →